Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
EMERYVILLE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented 6-month follow up data from its ongoing Phase 1 CORAL-CEPI and CORAL-BOOST studies, which are evaluating the company’s self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2, at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.
- “Previously, we reported initial 6-month data from CORAL-BOOST showing sustained high neutralizing antibody levels in the boost setting following Vaxzevria (AstraZeneca) primary series.
- “Current vaccines against COVID-19 have demonstrated susceptibility to loss of immunity over time, posing a greater burden on individuals and our health systems.
- Designation as virus-naïve/convalescent was driven by baseline anti-Nucleocapsid (N) IgG serology status (negative/positive respectively).
- To view Gritstone’s ECCMID presentations, visit ir.gritstonebio.com/investors/events .